A pre-clinical study to investigate the anti-diabetic potential of p-propoxybenzoic acid as a multi-target inhibitor in streptozotocin-nicotinamide induced type-2 diabetic rats.

IF 1.8 Q4 ENDOCRINOLOGY & METABOLISM
Journal of Diabetes and Metabolic Disorders Pub Date : 2022-12-31 eCollection Date: 2023-06-01 DOI:10.1007/s40200-022-01177-y
Keval Y Raval, Pravin R Tirgar
{"title":"A pre-clinical study to investigate the anti-diabetic potential of <i>p</i>-propoxybenzoic acid as a multi-target inhibitor in streptozotocin-nicotinamide induced type-2 diabetic rats.","authors":"Keval Y Raval, Pravin R Tirgar","doi":"10.1007/s40200-022-01177-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The study was undertaken to evaluate the anti-diabetic potential of <i>p-</i>propoxybenzoic acid (<i>p-</i>PBA).</p><p><strong>Methods: </strong>36 Sprague-Dawley rats of either sex were utilized for the study. Animals were injected with nicotinamide (230 mg/kg) followed by streptozotocin (65 mg/kg) to induce Type-2 Diabetes (T2DM). Animals with blood glucose levels (BGL) over 200 mg/kg were allocated in six groups. Three groups were treated with <i>p</i>-PBA dose of 100 mg/kg, 200 mg/kg and 300 mg/kg respectively; standard control group was treated with 5 mg/kg glibenclamide, while the other two groups were considered as normal control and disease control group. Body weight (BW) and BGL were recorded on Day 0, Day 7, Day 14, and Day 28. Glycosylated hemoglobin (HbA1c), serum insulin levels and lipid profile were recorded on Day 28. Animals were euthanized on Day 28 and the pancreas was isolated for histopathological examination.</p><p><strong>Results: </strong>Diabetic animals treated with <i>p-</i>PBA showed significant improvements in BW (<i>P</i> < 0.05) and BGL (<i>P</i> < 0.001) over 28 days. Levels of HbA1c (<i>P</i> < 0.05) and serum insulin (<i>P</i> < 0.001) were significantly regulated in animals treated with <i>p-</i>PBA. A significant decrease (<i>P</i> < 0.001) was observed in elevated levels of TC, TG, LDL cholesterol and VLDL cholesterol in animals treated with <i>p-</i>PBA. <i>p</i>-PBA significantly regulated the levels of HDL cholesterol (<i>P</i> < 0.001). A notable protective effect of <i>p-</i>PBA was observed through the histopathological examination of pancreas.</p><p><strong>Conclusion: </strong><i>p-</i>PBA can be characterized as a multi-target inhibiting anti-diabetic agent which can be evaluated against diabetic complications.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-022-01177-y.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"22 1","pages":"571-580"},"PeriodicalIF":1.8000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225424/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-022-01177-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 3

Abstract

Purpose: The study was undertaken to evaluate the anti-diabetic potential of p-propoxybenzoic acid (p-PBA).

Methods: 36 Sprague-Dawley rats of either sex were utilized for the study. Animals were injected with nicotinamide (230 mg/kg) followed by streptozotocin (65 mg/kg) to induce Type-2 Diabetes (T2DM). Animals with blood glucose levels (BGL) over 200 mg/kg were allocated in six groups. Three groups were treated with p-PBA dose of 100 mg/kg, 200 mg/kg and 300 mg/kg respectively; standard control group was treated with 5 mg/kg glibenclamide, while the other two groups were considered as normal control and disease control group. Body weight (BW) and BGL were recorded on Day 0, Day 7, Day 14, and Day 28. Glycosylated hemoglobin (HbA1c), serum insulin levels and lipid profile were recorded on Day 28. Animals were euthanized on Day 28 and the pancreas was isolated for histopathological examination.

Results: Diabetic animals treated with p-PBA showed significant improvements in BW (P < 0.05) and BGL (P < 0.001) over 28 days. Levels of HbA1c (P < 0.05) and serum insulin (P < 0.001) were significantly regulated in animals treated with p-PBA. A significant decrease (P < 0.001) was observed in elevated levels of TC, TG, LDL cholesterol and VLDL cholesterol in animals treated with p-PBA. p-PBA significantly regulated the levels of HDL cholesterol (P < 0.001). A notable protective effect of p-PBA was observed through the histopathological examination of pancreas.

Conclusion: p-PBA can be characterized as a multi-target inhibiting anti-diabetic agent which can be evaluated against diabetic complications.

Supplementary information: The online version contains supplementary material available at 10.1007/s40200-022-01177-y.

研究对丙氧基苯甲酸作为多靶点抑制剂对链脲佐菌素烟酰胺诱导的2型糖尿病大鼠的抗糖尿病潜力的临床前研究。
目的:评价对丙氧基苯甲酸(p-PBA)的抗糖尿病作用。动物注射烟酰胺(230 mg/kg),然后注射链脲佐菌素(65 mg/kg)以诱导2型糖尿病(T2DM)。将血糖水平(BGL)超过200mg/kg的动物分为六组。三组分别用100mg/kg、200mg/kg和300mg/kg的p-PBA剂量进行治疗;标准对照组给予格列本脲5mg/kg,其余两组分别为正常对照组和疾病对照组。在第0天、第7天、第14天和第28天记录体重(BW)和BGL。在第28天记录糖化血红蛋白(HbA1c)、血清胰岛素水平和脂质状况。在第28天对动物实施安乐死,并分离胰腺进行组织病理学检查。结果:p-PBA对糖尿病动物的BW有显著改善(p P P P p-PBA。显著下降(P p-PBA。p-PBA显著调节HDL胆固醇水平(p 胰腺组织病理学检查观察p-PBA。结论:p-PBA是一种多靶点的抗糖尿病药物,可用于糖尿病并发症的评估。补充信息:在线版本包含补充材料,请访问10.1007/s40200-022-01177-y。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes and Metabolic Disorders
Journal of Diabetes and Metabolic Disorders Medicine-Internal Medicine
CiteScore
4.80
自引率
3.60%
发文量
210
期刊介绍: Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信